cover image for Cell & Gene Pipeline Outlook: January 2026 Tracking the therapies shaping tomorrow’s care Prime Therapeutics /cell-gene-pipeline-outlook-january-2026 Prime Therapeutics’ Cell & Gene...

Dec. 28, 2024: cosibelimab Checkpoint Therapeutics resubmitted an application for its anti-programmed death ligand-1 (PD-L1) antibody, cosibelimab, for the treatment for adults with metastatic or...

Specialty Pharmacy Continuum

Forbes